决定异体 CAR T 细胞排斥与扩增的细胞和分子机制
Cellular and molecular mechanisms determining allogeneic CAR T cell rejection and expansion.
我们评估了11例接受单一批次cemacabtagene ansegedleucel(cema-cel)治疗的大B细胞淋巴瘤患者,cemacabtagene ansegedleucel是一种异体抗CD19 CAR T产品。
英文原题:The tumor microenvironment and immune targeting therapy in pediatric renal tumors.
本综述强调了若干免疫调节元件在包括 Wilms 瘤在内的多种儿童肾肿瘤的肿瘤微环境中所起的作用。
本文综述Wilms瘤等多种儿童肾脏肿瘤中,参与塑造肿瘤微环境的若干免疫调节因素。文章总结肾脏肿瘤中的先天性和适应性免疫细胞,以及免疫调节性细胞因子和其他蛋白的作用;并重点介绍PD-L1等免疫检查点调节分子,以及磷脂酰肌醇蛋白聚糖3、B7-H3、COX-2等免疫调节蛋白的表达和预测价值,并探讨其潜在治疗创新的转化前景。文章还讨论推动该领域发展的临床前模型现状。最后,介绍针对复发、难治或进展期儿童肾脏肿瘤的免疫调节策略临床试验,例如单克隆抗体和CAR-T(CAR-T)细胞治疗。
This review highlights the role of several immunomodulating elements contributing to the tumor microenvironment of various pediatric renal tumors including Wilms tumor. The roles of innate and adaptive immune cells in renal tumors are summarized as well as immunomodulatory cytokines and other proteins. The expression and the predictive role of checkpoint modulators like PD-L1 and immunomodulating proteins like glypican-3, B7-H3, COX-2 are highlighted with a translational view toward potential therapeutic innovations. We further discuss the current state of preclinical models in advancing this field of study. Finally, examples of clinical trials of immunomodulating strategies such as monoclonal antibodies and chimeric antigen receptor T (CAR-T) cells for relapsed/refractory/progressive pediatric renal tumors are described.
MEMBER ACCOUNT
登录成功会直接打开下一页。